Convertible visceral fat as a therapeutic target to curb obesity

Antonio Giordano,Andrea Frontini,Saverio Cinti

DOI: https://doi.org/10.1038/nrd.2016.31

IF: 112.288

2016-03-11

Nature Reviews Drug Discovery

Abstract:Key PointsObesity is a pathological enlargement of the adipose organ; this process involves the whitening and functional impairment of thermogenic brown adipose tissue and the inflammation of hypertrophied adipose depots.The occurrence of these two phenomena at visceral fat sites causes the most dangerous outcomes of obesity, including type 2 diabetes mellitus, dyslipidaemia, non-alcoholic fatty liver disease, cardiovascular disease and even some cancers. Visceral adipocytes are particularly vulnerable to lipid overload, possibly because of their developmental route and the reduced size at which they die, thereby promoting inflammation.Human and rodent visceral adipocytes exhibit remarkable cell plasticity. Indeed, such cells are particularly prone to re-convert into metabolically healthy, energy-dissipating adipocytes.Molecular targets and pathways that are involved in white-to-brown visceral adipocyte transdifferentiation are potential novel targets of anti-obesity drugs.Even the early steps of white-to-brown adipocyte transdifferentiation, which include adipocyte size reduction and mitochondriogenesis, could promote a healthy adipose phenotype and achieve effective therapeutic outcomes.

pharmacology & pharmacy,biotechnology & applied microbiology